Transactions & Cases Detail
Zymeworks raises US$58.5M in IPO
May 31, 2017
Pharmaceutical / Bio Life Sciences
63.6 Million USD
On May 3, 2017, Zymeworks closed its initial public offering of 4,500,000 common shares at an initial offering price of US$13.00 per share, for a total of US$58,500,000 in aggregate proceeds. Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC acted as joint book-running managers for the offering. Canaccord Genuity Corp. acted as lead manager and Cormark Securities Inc. acted as co-manager. The common shares of Zymeworks are listed on the New York Stock Exchange and the Toronto Stock Exchange under the symbol "ZYME".
On May 31, Zymeworks announced that it completed the previously announced sale of an additional 394,467 common shares to the underwriters of its initial public offering at a price of US$13 per share, for additional gross proceeds to Zymeworks of US$5,128,071, pursuant to the partial exercise by the underwriters of their over-allotment option
McCarthy Tétrault LLP advised the underwriters with a team led by David Frost that included Claire Sung, Ainslie Hurd, and Christopher Falk.